Peter Lawson

Analyst

Barclays

Equibles does not estimate personal net worth.

About Peter Lawson

Peter Lawson is recorded as Analyst at Barclays. Peter Lawson has spoken on 6 earnings calls across 5 companies, most recently for Iovance Biotherapeutics, Inc. on August 7, 2025. Those appearances were for Arcus Biosciences, Inc. (RCUS), Iovance Biotherapeutics, Inc. (IOVA), CytomX Therapeutics, Inc. (CTMX), Kura Oncology, Inc. (KURA) and Exelixis, Inc. (EXEL). The companies whose calls Peter Lawson spoke on are classified in the Healthcare sector.

Peter Lawson on recent calls

“Fred, just as you think about the guidance, just your level of confidence around proleukin, you mentioned it kind of accelerating in the second half, kind of what gives you that level of confidence.”

Analyst — Barclays, Iovance Biotherapeutics, Inc. Q2 FY2025 Earnings Call · August 7, 2025

“And that phase two, would that have a randomized component to it?”

Analyst — Barclays, CytomX Therapeutics, Inc. Q2 FY2025 Earnings Call · August 7, 2025

“I guess the first question was just off the And back in your comments about pipeline reprioritization, I wonder if you could talk through that a little bit more, and then whether you're exploring the adenosine inhibitor further, if that's the program ended.”

Analyst — Barclays, Arcus Biosciences, Inc. Q1 FY2025 Earnings Call · May 6, 2025

“As we think about expectations for patients previously treated in the pivotal study, how should we think about that versus what we saw in the Phase 1 published data?”

Analyst — Barclays, Kura Oncology, Inc. Q3 FY2024 Earnings Call · November 7, 2024

“I'll try and make it a multi-part of you. Just on your HIF2 alpha, the data we're going to see early 2024, do you think that differentiation starts emerging, whether it's in ORR, or do you think we have to wait to see that emerging in PFS?”

Analyst — Barclays, Arcus Biosciences, Inc. Q3 FY2023 Earnings Call · November 7, 2023